IS5405A - Prostaglandín gerandefni og notkun þeirra til að meðhöndla beintruflanir - Google Patents

Prostaglandín gerandefni og notkun þeirra til að meðhöndla beintruflanir

Info

Publication number: IS5405A
Authority: IS; Iceland
Prior art keywords: treatment; bone disorders; prostaglandin agonists; prostaglandin; agonists
Prior art date: 1997-10-10

Application number

IS5405A

Other languages

English (en)

Inventor

O'keefe Cameron Kimberly

Allen Lefker Bruce

Louis Rosati Robert

Original Assignee

Pfizer Inc.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-10-10

Filing date

2000-03-14

Publication date

2000-03-14

2000-03-14 Application filed by Pfizer Inc. filed Critical Pfizer Inc.

2000-03-14 Publication of IS5405A publication Critical patent/IS5405A/is

Links

208000020084 Bone disease Diseases 0.000 title 1
239000000556 agonist Substances 0.000 title 1
150000003180 prostaglandins Chemical class 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/70—Sulfur atoms
- C07D213/71—Sulfur atoms to which a second hetero atom is attached
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
- C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
- C07C311/19—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/45—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups at least one of the singly-bound nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom, e.g. N-acylaminosulfonamides
- C07C311/46—Y being a hydrogen or a carbon atom
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/84—Sulfur atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Physical Education & Sports Medicine (AREA)
Orthopedic Medicine & Surgery (AREA)
Rheumatology (AREA)
Ophthalmology & Optometry (AREA)
Urology & Nephrology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Plural Heterocyclic Compounds (AREA)
Pyridine Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
Heterocyclic Compounds Containing Sulfur Atoms (AREA)
Furan Compounds (AREA)
Thiazole And Isothizaole Compounds (AREA)
Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
Pyrrole Compounds (AREA)

IS5405A 1997-10-10 2000-03-14 Prostaglandín gerandefni og notkun þeirra til að meðhöndla beintruflanir IS5405A (is)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US6172797P	1997-10-10	1997-10-10
PCT/IB1998/001540 WO1999019300A1 (en)	1997-10-10	1998-10-05	Prostaglandin agonists and their use to treat bone disorders

Publications (1)

Publication Number	Publication Date
IS5405A true IS5405A (is)	2000-03-14

Family

ID=22037728

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IS5405A IS5405A (is)	1997-10-10	2000-03-14	Prostaglandín gerandefni og notkun þeirra til að meðhöndla beintruflanir

Country Status (44)

Country	Link
US (2)	US6498172B1 (is)
EP (1)	EP1021410B1 (is)
JP (3)	JP3664651B2 (is)
KR (1)	KR100369697B1 (is)
CN (2)	CN1566096A (is)
AP (1)	AP1156A (is)
AR (1)	AR015954A1 (is)
AT (1)	ATE349428T1 (is)
AU (1)	AU731509B2 (is)
BG (1)	BG65238B1 (is)
BR (1)	BR9813028A (is)
CA (1)	CA2305548C (is)
DE (1)	DE69836752T2 (is)
DK (1)	DK1021410T3 (is)
DZ (1)	DZ2621A1 (is)
EA (1)	EA003396B1 (is)
ES (1)	ES2277390T3 (is)
GT (2)	GT199800158AA (is)
HN (1)	HN1998000157A (is)
HR (1)	HRP20000201B1 (is)
HU (1)	HUP0100101A3 (is)
ID (1)	ID24836A (is)
IL (2)	IL134851A0 (is)
IS (1)	IS5405A (is)
MA (1)	MA26551A1 (is)
MY (1)	MY129189A (is)
NO (1)	NO316733B1 (is)
NZ (1)	NZ503165A (is)
OA (1)	OA11346A (is)
PA (1)	PA8461301A1 (is)
PE (1)	PE121199A1 (is)
PL (1)	PL340014A1 (is)
PT (1)	PT1021410E (is)
RS (1)	RS50012B (is)
SA (2)	SA98190804B1 (is)
SI (1)	SI1021410T1 (is)
SK (1)	SK286136B6 (is)
TN (1)	TNSN98182A1 (is)
TR (1)	TR200000927T2 (is)
TW (1)	TW570913B (is)
UA (1)	UA67754C2 (is)
UY (1)	UY25204A1 (is)
WO (1)	WO1999019300A1 (is)
ZA (1)	ZA989230B (is)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
UA67754C2 (uk)	1997-10-10	2004-07-15	Пфайзер, Інк.	Агоністи простагландину, фармацевтична композиція на їх основі (варіанти), спосіб нарощення та збереження кісткової маси у хребетних та спосіб лікування (варіанти)
EP1000619A3 (en) *	1998-06-23	2002-07-24	Pfizer Products Inc.	Method for treating glaucoma
WO2000051980A1 (en)	1999-03-05	2000-09-08	The Procter & Gamble Company	C16 unsaturated fp-selective prostaglandins analogs
US6894175B1 (en)	1999-08-04	2005-05-17	The Procter & Gamble Company	2-Decarboxy-2-phosphinico prostaglandin derivatives and methods for their preparation and use
TWI262185B (en) *	1999-10-01	2006-09-21	Eisai Co Ltd	Carboxylic acid derivatives having anti-hyperglycemia and anti-hyperlipemia action, and pharmaceutical composition containing the derivatives
ATE327751T1 (de)	2000-01-31	2006-06-15	Pfizer Prod Inc	Verwendung von aktivatoren des prostaglandinrezeptores 4 zur behandlung von akuter oder chronischer niereninsuffizienz
US20010056060A1 (en) *	2000-02-07	2001-12-27	Cameron Kimberly O.	Treatment of osteoporsis with EP2/EP4 receptor selective agonists
US20020013294A1 (en)	2000-03-31	2002-01-31	Delong Mitchell Anthony	Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives
US20020172693A1 (en)	2000-03-31	2002-11-21	Delong Michell Anthony	Compositions and methods for treating hair loss using non-naturally occurring prostaglandins
US20020037914A1 (en)	2000-03-31	2002-03-28	Delong Mitchell Anthony	Compositions and methods for treating hair loss using C16-C20 aromatic tetrahydro prostaglandins
AU2002365969A1 (en) *	2001-11-20	2003-06-10	Scott Bruder	Flowable osteogenic and chondrogenic compositions
WO2003045371A1 (en) *	2001-11-30	2003-06-05	Pfizer Products Inc.	Pharmaceutical compositions and methods for administering ep2 receptor selective agonists
AP1781A (en) *	2001-11-30	2007-09-27	Pfizer	Controlled release polymeric compositions of bone growth promoting compounds.
PY0300568A (es) *	2002-01-31	2004-10-01	Pfizer Prod Inc	Metabolitos del acido(3-{[4-terc-butilbencil)-(piridin-3-sulfonil)amino]metil}fenoxi)acetico
JP2005532291A (ja)	2002-04-12	2005-10-27	ファイザー株式会社	抗炎症薬および鎮痛薬としてのピラゾール化合物
AU2003233670A1 (en)	2002-05-24	2003-12-12	Pharmacia Corporation	Sulfone liver x-receptor modulators
AU2003241601A1 (en)	2002-05-24	2003-12-12	Pharmacia Corporation	Anilino liver x-receptor modulators
JP2006021998A (ja) *	2002-07-18	2006-01-26	Ono Pharmaceut Co Ltd	Ｅｐ２アゴニストを有効成分とする月経困難症治療剤
DK1563846T3 (da)	2002-10-10	2012-12-17	Ono Pharmaceutical Co	Endogene reparationsfaktorproduktionsfremmere
GB0302094D0 (en)	2003-01-29	2003-02-26	Pharmagene Lab Ltd	EP4 receptor antagonists
AU2004216898A1 (en) *	2003-03-04	2004-09-16	Pfizer Products Inc.	Use of EP2 selective receptor agonists in medical treatment
WO2005009468A1 (ja)	2003-07-25	2005-02-03	Ono Pharmaceutical Co., Ltd.	軟骨関連疾患治療剤
WO2005027931A1 (en) *	2003-09-19	2005-03-31	Pfizer Products Inc.	Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and an ep2 or ep4 selective agonist
GB0324269D0 (en)	2003-10-16	2003-11-19	Pharmagene Lab Ltd	EP4 receptor antagonists
US20050203086A1 (en) *	2004-03-04	2005-09-15	Pfizer Inc.	Methods of treatment using an EP2 selective receptor agonist
BRPI0512342A (pt) *	2004-06-21	2008-03-04	Pharmacia & Upjohn Co Llc	métodos para aumento ósseo
EP1841749A1 (en)	2004-09-02	2007-10-10	Metabasis Therapeutics, Inc.	Derivatives of thiazole and thiadiazole inhibitors of tyrosine phosphatases
JP4893999B2 (ja)	2004-10-22	2012-03-07	小野薬品工業株式会社	吸入用医薬組成物
US8604055B2 (en)	2004-12-31	2013-12-10	Dr. Reddy's Laboratories Ltd.	Substituted benzylamino quinolines as cholesterol ester-transfer protein inhibitors
US9040558B2 (en)	2004-12-31	2015-05-26	Dr. Reddy's Laboratories Ltd.	Substituted benzylamino quinolines as cholesterol ester-transfer protein inhibitors
CA2610692C (en)	2005-06-03	2014-11-25	Ono Pharmaceutical Co., Ltd.	Ep2 agonists which may have an ep3 agonistic effect for regeneration and/or protection of nerves
US7915316B2 (en)	2005-08-22	2011-03-29	Allergan, Inc	Sulfonamides
US7696235B2 (en)	2005-08-29	2010-04-13	Allergan, Inc.	EP2 receptor agonists for treating glaucoma
CN101495452B (zh) *	2006-07-28	2012-04-25	辉瑞产品公司	Ep2激动剂
AU2007280130B2 (en)	2006-07-28	2011-09-22	Pfizer Products Inc.	EP2 agonists
JP5271272B2 (ja)	2006-11-16	2013-08-21	ジェンムスファーマインコーポレイティド	Ａ型インフルエンザウィルス感染の治療のための薬剤としてのｅｐ２およびｅｐ４作動薬
EP2094839B1 (en) *	2006-12-08	2020-02-05	University of Rochester	Expansion of hematopoietic stem cells
RU2522456C2 (ru) *	2007-08-21	2014-07-10	Синомикс, Инк.	Соединения, ингибирующие (блокирующие) горький вкус, способы их применения и получения
WO2009027811A2 (en) *	2007-08-29	2009-03-05	Pfizer Products Inc.	Polymorphs of 3- ( ( (4-tert-butyl-benzyl) - (pyridine-3-sulfonyl) -amino) -methyl) -phenoxy) -acetic acid sodium salt or a hydrate thereof and methods for making the same
WO2009027803A2 (en) *	2007-08-29	2009-03-05	Pfizer Products Inc.	Polymorphs of (3-(((4-tert-butyl-benzyl)-(pyridine-3-sulfonyl)-amino)-methyl)- phenoxy)-acetic acid, free acid
US20110046385A1 (en) *	2007-08-29	2011-02-24	Pfizer Products Inc.	Polymorphs Of Prostaglandin Agonists And Methods For Making The Same
SI2264009T1 (sl)	2008-03-12	2019-05-31	Ube Industries, Ltd.	Spojina piridilaminoocetne kisline
EP2149551A1 (de)	2008-07-30	2010-02-03	Bayer Schering Pharma AG	N-(Indol-3-ylalkyl)-(hetero)arylamidderivate als Modulatoren des EP2-Rezeptors
EP2149554A1 (de)	2008-07-30	2010-02-03	Bayer Schering Pharma Aktiengesellschaft	Indolylamide als Modulatoren des EP2-Rezeptors
EP2149552A1 (de)	2008-07-30	2010-02-03	Bayer Schering Pharma AG	5,6 substituierte Benzamid-Derivate als Modulatoren des EP2-Rezeptors
HUE026742T2 (en)	2009-03-30	2016-07-28	Ube Industries	A pharmaceutical composition for the treatment or prevention of glaucoma
WO2010116270A1 (en)	2009-04-10	2010-10-14	Pfizer Inc.	Ep2/4 agonists
KR20120101722A (ko)	2009-12-25	2012-09-14	우베 고산 가부시키가이샤	아미노피리딘 화합물
US9068166B2 (en)	2010-09-16	2015-06-30	Industry-Academic Cooperation Foundation Yonsei University	Use of compounds for inducing differentiation of mesenchymal stem cells to chondrocytes
WO2013024358A2 (en)	2011-08-18	2013-02-21	Dr. Reddy's Laboratories Ltd.	Substituted heterocyclic amine compounds as cholestryl ester-transfer protein (cetp) inhibitors
MX352074B (es)	2011-09-27	2017-11-08	Dr Reddys Laboratories Ltd	Derivados de 5-bencilaminometil-6-aminopirazolo [3,4-b] piridina como inhibidores de proteina de transferencia de ester de colesterilo (cetp) utiles para el tratamiento de aterosclerosis.
US8772541B2 (en) *	2011-12-15	2014-07-08	University of Pittsburgh—of the Commonwealth System of Higher Education	Cannabinoid receptor 2 (CB2) inverse agonists and therapeutic potential for multiple myeloma and osteoporosis bone diseases
JP6400479B2 (ja)	2012-10-29	2018-10-03	株式会社カルディオ	肺疾患特異的治療剤
US9487485B2 (en)	2013-02-28	2016-11-08	Takeda Pharmaceutical Company Limited	Method for producing sulfonyl chloride compound
HK1220457A1 (zh)	2013-03-28	2017-05-05	宇部兴产株式会社	取代联芳基化合物
JP6449166B2 (ja)	2013-10-15	2019-01-09	小野薬品工業株式会社	薬剤溶出性ステントグラフト
JP2017206444A (ja) *	2014-09-26	2017-11-24	宇部興産株式会社	置換フェニル化合物
CN114591227A (zh) *	2021-12-28	2022-06-07	上海冬洋生物科技有限公司	一种ep2受体选择性的前列腺素e2激动剂的制备方法

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR897566A (fr)	1942-08-28	1945-03-26	Bopp & Reuther Gmbh	Machine à rotors
US3442890A (en)	1965-06-15	1969-05-06	Mead Johnson & Co	Substituted 3-benzazocin-16-ones
US3528961A (en)	1966-08-16	1970-09-15	Allied Chem	Monoazo dyes from e-caprolactam
US3780095A (en)	1970-04-08	1973-12-18	Byk Gulden Lomberg Chem Fab	Acylated anilino-carboxylic acids and their salts
US3987091A (en)	1973-04-12	1976-10-19	Merck & Co., Inc.	11,12-secoprostaglandins
US4033996A (en)	1973-04-25	1977-07-05	Merck & Co., Inc.	8-Aza-9-oxo(and dioxo)-thia-11,12-secoprostaglandins
JPS5019756A (is)	1973-06-25	1975-03-01
SE7414770L (is)	1973-12-13	1975-06-16	Merck & Co Inc
DK366475A (da)	1974-08-30	1976-03-01	Merck & Co Inc	Fremgangsmade til fremstilling af aryloxy- eller arylthioholdige secoprostaglandiner
US3991106A (en)	1974-09-13	1976-11-09	Merck & Co., Inc.	16-Ethers of 8-aza-9-dioxothia-11,12-seco-prostaglandins
US4055596A (en) *	1974-09-13	1977-10-25	Merck & Co., Inc.	11,12-Seco-prostaglandins
US4175203A (en)	1976-12-17	1979-11-20	Merck & Co., Inc.	Interphenylene 11,12-secoprostaglandins
US4112236A (en)	1977-04-04	1978-09-05	Merck & Co., Inc.	Interphenylene 8-aza-9-dioxothia-11,12-secoprostaglandins
US4097601A (en) *	1977-08-26	1978-06-27	Pfizer Inc.	Bone deposition by 2-descarboxy-2-(tetrazol-5-yl)-11-dexosy-16-aryl prostaglandins
US4243678A (en)	1977-12-30	1981-01-06	Byk Gulden Lomberg Chemische Fabrik Gmbh	Acylhydrocarbylaminoalkanoic acids, compositions and uses
DE3000377A1 (de)	1980-01-07	1981-07-09	Boehringer Mannheim Gmbh, 6800 Mannheim	Neue sulfonamide, verfahren zu deren herstellung sowie diese verbindungen enthaltende arzneimittel
DE3042482A1 (de)	1980-11-11	1982-06-24	A. Nattermann & Cie GmbH, 5000 Köln	N-benzoyl- (omega) -anilinoalkancarbonsaeuren, -salze und -ester, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische praeparate
CA1214170A (fr)	1981-06-16	1986-11-18	Patrick Choay	Procedes de preparation de nouveaux composes du type arylbenzenesulfonamide
FI832935A7 (fi)	1982-08-20	1984-02-21	Midit	Derivat av w-aminosyror, deras framstaellning samt dessa derivat innehaollande blandningar
DE3719046A1 (de)	1987-06-06	1988-12-15	Basf Ag	Verwendung von salzen von sulfonamidcarbonsaeuren als korrosionsinhibitoren in waessrigen systemen
US5084466A (en) *	1989-01-31	1992-01-28	Hoffmann-La Roche Inc.	Novel carboxamide pyridine compounds which have useful pharmaceutical utility
US5081152A (en)	1989-07-05	1992-01-14	Kotobuki Seiyaku Co., Ltd.	Azulene derivatives as thromboxane a2 and prostaglandin endoperoxide receptor antagonist
JPH0467105A (ja) *	1990-07-09	1992-03-03	Nippon Telegr & Teleph Corp <Ntt>	偏波保持光ファイバ
GB9110722D0 (en) *	1991-05-17	1991-07-10	Fujisawa Pharmaceutical Co	Amine derivatives
GB9116732D0 (en) *	1991-08-02	1991-09-18	Fujisawa Pharmaceutical Co	Indole derivatives
CA2113787A1 (en) *	1993-01-29	1994-07-30	Nobuyuki Hamanaka	Carbocyclic sulfonamides
HN1996000101A (es)	1996-02-28	1997-06-26	Inc Pfizer	Terapia combinada para la osteoporosis
DE19648793A1 (de)	1996-11-26	1998-05-28	Basf Ag	Neue Benzamide und deren Anwendung
UA59384C2 (uk)	1996-12-20	2003-09-15	Пфайзер, Інк.	Похідні сульфонамідів та амідів як агоністи простагландину, фармацевтична композиція та способи лікування на їх основі
AUPO440696A0 (en) *	1996-12-30	1997-01-23	Fujisawa Pharmaceutical Co., Ltd.	New use
UA67754C2 (uk)	1997-10-10	2004-07-15	Пфайзер, Інк.	Агоністи простагландину, фармацевтична композиція на їх основі (варіанти), спосіб нарощення та збереження кісткової маси у хребетних та спосіб лікування (варіанти)
WO2003045371A1 (en) *	2001-11-30	2003-06-05	Pfizer Products Inc.	Pharmaceutical compositions and methods for administering ep2 receptor selective agonists
PY0300568A (es) *	2002-01-31	2004-10-01	Pfizer Prod Inc	Metabolitos del acido(3-{[4-terc-butilbencil)-(piridin-3-sulfonil)amino]metil}fenoxi)acetico

1998
- 1998-05-10 UA UA2000042002A patent/UA67754C2/uk unknown
- 1998-10-05 EP EP98944169A patent/EP1021410B1/en not_active Expired - Lifetime
- 1998-10-05 TR TR2000/00927T patent/TR200000927T2/xx unknown
- 1998-10-05 DE DE69836752T patent/DE69836752T2/de not_active Expired - Lifetime
- 1998-10-05 CN CNA2004100385354A patent/CN1566096A/zh active Pending
- 1998-10-05 SK SK475-2000A patent/SK286136B6/sk not_active IP Right Cessation
- 1998-10-05 ID IDW20000647A patent/ID24836A/id unknown
- 1998-10-05 JP JP2000515873A patent/JP3664651B2/ja not_active Expired - Fee Related
- 1998-10-05 EA EA200000298A patent/EA003396B1/ru not_active IP Right Cessation
- 1998-10-05 RS YUP-184/00A patent/RS50012B/sr unknown
- 1998-10-05 DK DK98944169T patent/DK1021410T3/da active
- 1998-10-05 KR KR10-2000-7003851A patent/KR100369697B1/ko not_active Expired - Fee Related
- 1998-10-05 CN CNB988100266A patent/CN1211367C/zh not_active Expired - Fee Related
- 1998-10-05 PT PT98944169T patent/PT1021410E/pt unknown
- 1998-10-05 IL IL13485198A patent/IL134851A0/xx active IP Right Grant
- 1998-10-05 US US09/367,970 patent/US6498172B1/en not_active Expired - Fee Related
- 1998-10-05 HR HR980440A patent/HRP20000201B1/xx not_active IP Right Cessation
- 1998-10-05 BR BR9813028-5A patent/BR9813028A/pt not_active Application Discontinuation
- 1998-10-05 CA CA002305548A patent/CA2305548C/en not_active Expired - Fee Related
- 1998-10-05 HU HU0100101A patent/HUP0100101A3/hu unknown
- 1998-10-05 NZ NZ503165A patent/NZ503165A/en unknown
- 1998-10-05 ES ES98944169T patent/ES2277390T3/es not_active Expired - Lifetime
- 1998-10-05 SI SI9830873T patent/SI1021410T1/sl unknown
- 1998-10-05 AU AU91815/98A patent/AU731509B2/en not_active Ceased
- 1998-10-05 WO PCT/IB1998/001540 patent/WO1999019300A1/en not_active Ceased
- 1998-10-05 PL PL98340014A patent/PL340014A1/xx unknown
- 1998-10-05 AT AT98944169T patent/ATE349428T1/de not_active IP Right Cessation
- 1998-10-06 HN HN1998000157A patent/HN1998000157A/es unknown
- 1998-10-06 PA PA19988461301A patent/PA8461301A1/es unknown
- 1998-10-07 TW TW087116614A patent/TW570913B/zh not_active IP Right Cessation
- 1998-10-07 MY MYPI98004598A patent/MY129189A/en unknown
- 1998-10-08 UY UY25204A patent/UY25204A1/es not_active IP Right Cessation
- 1998-10-08 AP APAP/P/1998/001356A patent/AP1156A/en active
- 1998-10-09 TN TNTNSN98182A patent/TNSN98182A1/fr unknown
- 1998-10-09 PE PE1998000956A patent/PE121199A1/es not_active Application Discontinuation
- 1998-10-09 AR ARP980105053A patent/AR015954A1/es active IP Right Grant
- 1998-10-09 ZA ZA9809230A patent/ZA989230B/xx unknown
- 1998-10-09 GT GT199800158AK patent/GT199800158AA/es unknown
- 1998-10-09 GT GT199800158A patent/GT199800158A/es unknown
- 1998-10-09 MA MA25288A patent/MA26551A1/fr unknown
- 1998-10-10 DZ DZ980231A patent/DZ2621A1/xx active
- 1998-11-23 SA SA98190804A patent/SA98190804B1/ar unknown
- 1998-11-23 SA SA6260449A patent/SA06260449B1/ar unknown
2000
- 2000-03-02 IL IL134851A patent/IL134851A/en not_active IP Right Cessation
- 2000-03-14 IS IS5405A patent/IS5405A/is unknown
- 2000-03-31 OA OA1200000097A patent/OA11346A/en unknown
- 2000-04-05 NO NO20001754A patent/NO316733B1/no not_active IP Right Cessation
- 2000-04-07 BG BG104315A patent/BG65238B1/bg unknown
2002
- 2002-09-25 US US10/256,198 patent/US7442702B2/en not_active Expired - Fee Related
2003
- 2003-06-12 JP JP2003167713A patent/JP4031736B2/ja not_active Expired - Fee Related
2007
- 2007-04-25 JP JP2007115825A patent/JP4796006B2/ja not_active Expired - Fee Related

Also Published As

Publication number	Publication date
CN1275123A (zh)	2000-11-29
JP2007246532A (ja)	2007-09-27
OA11346A (en)	2003-12-11
SA98190804B1 (ar)	2006-07-30
IL134851A (en)	2007-06-17
PE121199A1 (es)	1999-12-02
RS50012B (sr)	2008-09-29
TNSN98182A1 (fr)	2005-03-15
KR100369697B1 (ko)	2003-02-05
EA200000298A1 (ru)	2000-10-30
ID24836A (id)	2000-08-24
DE69836752D1 (de)	2007-02-08
CA2305548C (en)	2008-12-02
HRP20000201B1 (en)	2003-06-30
DE69836752T2 (de)	2007-10-11
EA003396B1 (ru)	2003-04-24
NO316733B1 (no)	2004-04-14
US20030078261A1 (en)	2003-04-24
HN1998000157A (es)	1999-06-02
CN1211367C (zh)	2005-07-20
AU9181598A (en)	1999-05-03
JP4796006B2 (ja)	2011-10-19
NO20001754L (no)	2000-06-07
BG104315A (en)	2000-12-29
DZ2621A1 (fr)	2003-03-08
BR9813028A (pt)	2000-08-15
AP1156A (en)	2003-06-30
SA06260449B1 (ar)	2007-08-07
SI1021410T1 (sl)	2007-06-30
TR200000927T2 (tr)	2000-11-21
UY25204A1 (es)	2000-12-29
ES2277390T3 (es)	2007-07-01
CN1566096A (zh)	2005-01-19
AU731509B2 (en)	2001-03-29
KR20010031035A (ko)	2001-04-16
UA67754C2 (uk)	2004-07-15
PL340014A1 (en)	2001-01-15
NO20001754D0 (no)	2000-04-05
HRP20000201A2 (en)	2000-06-30
HUP0100101A3 (en)	2001-12-28
JP4031736B2 (ja)	2008-01-09
HUP0100101A2 (hu)	2001-06-28
TW570913B (en)	2004-01-11
WO1999019300A1 (en)	1999-04-22
HK1031884A1 (en)	2001-06-29
ZA989230B (en)	2000-04-10
IL134851A0 (en)	2001-05-20
SK286136B6 (sk)	2008-04-07
US7442702B2 (en)	2008-10-28
PT1021410E (pt)	2007-02-28
GT199800158A (es)	2000-04-01
NZ503165A (en)	2001-07-27
US6498172B1 (en)	2002-12-24
PA8461301A1 (es)	2000-05-24
JP3664651B2 (ja)	2005-06-29
JP2001519414A (ja)	2001-10-23
GT199800158AA (es)	2000-04-01
CA2305548A1 (en)	1999-04-22
EP1021410B1 (en)	2006-12-27
AR015954A1 (es)	2001-05-30
DK1021410T3 (da)	2007-04-02
MY129189A (en)	2007-03-30
MA26551A1 (fr)	2004-12-20
SK4752000A3 (en)	2001-05-10
ATE349428T1 (de)	2007-01-15
SA98190804A (ar)	2005-12-03
JP2004155759A (ja)	2004-06-03
BG65238B1 (bg)	2007-09-28
YU18400A (sh)	2003-08-29
AP9801356A0 (en)	1998-12-31
EP1021410A1 (en)	2000-07-26

Publication	Publication Date	Title
IS5405A (is)	2000-03-14	Prostaglandín gerandefni og notkun þeirra til að meðhöndla beintruflanir
NO20004098D0 (no)	2000-08-16	FremgangsmÕter og preparater for behandling av makrofag- formidlede lidelser
NO972972D0 (no)	1997-06-25	Sammensetninger for behandling av dermatologiske forstyrrelser og metoder for deres anvendelse
IS2107B (is)	2006-05-15	Arýlsúlfónamíð og hliðstæður þeirra og notkun þeirra við meðhöndlun taugahrörnunarsjúkdóma
NO20005190L (no)	2000-11-30	Terapeutiske angiogene faktorer og fremgangsmåter til anvendelse derav
EE9800158A (et)	1998-12-15	Epinastiin kasutamiseks valude ravis
NO983235L (no)	1998-07-14	Fikstur og protese innbefattende samme
NO972125L (no)	1997-07-02	Hemorroideblandinger og fremgangsmåte for anvendelse
NO20014560D0 (no)	2001-09-19	Quinasoliner og terapautisk anvendelse derav
PT1212317E (pt)	2005-02-28	Derivados de indole e sua utilizacao no tratamento de osteoporose entre outras aplicacoes
ID18679A (id)	1998-04-30	Penggunaan terapi lanjutan
DK0961609T3 (da)	2003-08-04	Fremgangsmåde til forbedring af sundhedstilstanden af hår og hovedbund
NO984836L (no)	1998-12-16	Substituerte benzylaminer og deres anvendelse for behandling av depresjon
NO20001412D0 (no)	2000-03-17	Sammensetninger og fremgangsmåter ved behandling av respiratoriske forstyrrelser
IS7203A (is)	2004-03-31	4[píperidín-4-ýliden-(3-karbamólýlfenýl)metýl]bensamíðafleiður og notkun þeirra til að meðhöndla verki, mænuskaða eða maga- og garnasjúkdóma
FI951060A7 (fi)	1995-09-09	Formulaatioita ja hoitomenetelmiä
DK1114821T3 (da)	2004-02-02	Benzopyraner og disses anvendelse som terapeutiske midler
NO986034D0 (no)	1998-12-22	Kombinasjoner omfattende VX 478, ZidovudÞn, FTC og/eller 3TC for anvendelse
NO20012738D0 (no)	2001-06-01	Terapeutiske produkter og anvendelse derav
PT925039E (pt)	2002-06-28	Aparelhos para tratamento de ortopedia funcional dento facial e parodontologia
NO326826B1 (no)	2009-02-23	Alfa-aminosyreamider, fremstilling og terapeutisk anvendelse derav
GB9708067D0 (en)	1997-06-11	Rapid and long lasting biocidal system and its use to the treatment of hard surfaces
ID30458A (id)	2001-12-06	Osanetan dalam pengobatan gangguan jiwa
IT232384Y1 (it)	1999-12-17	Apparecchiatura per ipotermia e/o ipertermia terapeutica.
IS5324A (is)	1999-12-28	(S) 2-Metýlamínó-2-fenýl-n-bútýl 3,4,5-trímetoxý-bensóat, notkun þess til meðferðar á langvinnum sársauka